Literature DB >> 12802274

c-Cbl is a critical modulator of the Ron tyrosine kinase receptor.

Lorenza Penengo1, Chanan Rubin, Yosef Yarden, Giovanni Gaudino.   

Abstract

Ron, the receptor tyrosine kinase (RTK) for the macrophage stimulating protein (MSP), activates multiple signaling pathways by recruiting several positive regulators to a multifunctional docking site. Here we show that stimulation by MSP also recruits a negative regulator, the c-Cbl ubiquitin ligase, to the multifunctional docking site as well as to a juxtamembrane tyrosine autophosphorylation site. c-Cbl recruitment to these two sites results in polyubiquitylation of Ron molecules, which are subsequently sorted for endocytosis and degradation. Both the phosphotyrosine binding domain of c-Cbl and its RING domain are essential for downregulation of Ron. Although Ron and c-Cbl are found also in physical complexes that include Grb2, these associations are insufficient for productive ubiquitylation of Ron. Our results shed light on the mechanism of receptor desensitization mediated by c-Cbl and its binding partner Grb2.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12802274     DOI: 10.1038/sj.onc.1206585

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  19 in total

Review 1.  Degradation of activated protein kinases by ubiquitination.

Authors:  Zhimin Lu; Tony Hunter
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

Review 2.  Endocytosis of receptor tyrosine kinases.

Authors:  Lai Kuan Goh; Alexander Sorkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-05-01       Impact factor: 10.005

3.  Short-Form Ron Promotes Spontaneous Breast Cancer Metastasis through Interaction with Phosphoinositide 3-Kinase.

Authors:  Xuemei Liu; Ling Zhao; Yoko S Derose; Yi-Chun Lin; Magdalena Bieniasz; Henok Eyob; Saundra S Buys; Leigh Neumayer; Alana L Welm
Journal:  Genes Cancer       Date:  2011-07

Review 4.  c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses.

Authors:  Christine B F Thien; Wallace Y Langdon
Journal:  Biochem J       Date:  2005-10-15       Impact factor: 3.857

Review 5.  MSP-RON signalling in cancer: pathogenesis and therapeutic potential.

Authors:  Hang-Ping Yao; Yong-Qing Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Nat Rev Cancer       Date:  2013-07       Impact factor: 60.716

6.  The carboxyl terminus of VEGFR-2 is required for PKC-mediated down-regulation.

Authors:  Amrik J Singh; Rosana D Meyer; Hamid Band; Nader Rahimi
Journal:  Mol Biol Cell       Date:  2005-01-26       Impact factor: 4.138

7.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

Review 8.  Molecular mechanisms of SH2- and PTB-domain-containing proteins in receptor tyrosine kinase signaling.

Authors:  Melany J Wagner; Melissa M Stacey; Bernard A Liu; Tony Pawson
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

9.  Structural basis for a novel intrapeptidyl H-bond and reverse binding of c-Cbl-TKB domain substrates.

Authors:  Cherlyn Ng; Rebecca A Jackson; Jan P Buschdorf; Qingxiang Sun; Graeme R Guy; J Sivaraman
Journal:  EMBO J       Date:  2008-02-14       Impact factor: 11.598

10.  HIV-1 Tat mediates degradation of RON receptor tyrosine kinase, a regulator of inflammation.

Authors:  Parisa Kalantari; Omid F Harandi; Pamela A Hankey; Andrew J Henderson
Journal:  J Immunol       Date:  2008-07-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.